156 related articles for article (PubMed ID: 37573150)
1. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.
Jandial A; Lad D; Jain A; Khadwal A; Singh C; Prakash G; Suri V; Sreedharanunni S; Sachdeva MUS; Ray P; Varma N; Varma S; Malhotra P
Transpl Infect Dis; 2023 Oct; 25(5):e14123. PubMed ID: 37573150
[TBL] [Abstract][Full Text] [Related]
2. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Satlin MJ; Vardhana S; Soave R; Shore TB; Mark TM; Jacobs SE; Walsh TJ; Gergis U
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1808-14. PubMed ID: 26150022
[TBL] [Abstract][Full Text] [Related]
3. Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma.
Rahman S; Rybicki L; Ky Hamilton B; Pohlman B; Jagadeesh D; Cober E; Kalaycio M; Dean R; Sobecks R; Mossad SB; Majhail NS
Transpl Infect Dis; 2019 Aug; 21(4):e13114. PubMed ID: 31102556
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.
Drayson MT; Bowcock S; Planche T; Iqbal G; Pratt G; Yong K; Wood J; Raynes K; Higgins H; Dawkins B; Meads D; Hulme CT; Whittaker AC; Hawkey P; Low E; Dunn JA
Health Technol Assess; 2019 Nov; 23(62):1-94. PubMed ID: 31690402
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
[TBL] [Abstract][Full Text] [Related]
6. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Dhakal B; Thapa B; Dong H; Tarima S; Chhabra S; D'Souza A; Drobyski W; Abid M; Shah N; Fenske T; Longo W; Hari P; Hamadani M
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e775-e781. PubMed ID: 34257042
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study.
Yeshurun M; Vaxman I; Shargian L; Yahav D; Bishara J; Pasvolsky O; Wolach O; Lahav M; Gurion R; Magen H; Vidal L; Herscovici C; Peck A; Moshe M; Sela-Navon M; Naparstek E; Raanani P; Rozovski U
Clin Microbiol Infect; 2018 Jul; 24(7):749-754. PubMed ID: 29208561
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Prophylactic Levofloxacin in Pediatric and Adult Hematopoietic Stem Cell Transplantation Patients.
Gardner JC; Courter JD; Dandoy CE; Davies SM; Teusink-Cross A
Transplant Cell Ther; 2022 Mar; 28(3):167.e1-167.e5. PubMed ID: 34875405
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation.
Copeland V; McLaughlin M; Trifilio S
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29080369
[TBL] [Abstract][Full Text] [Related]
10. Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence.
Wang CH; Chang FY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2018 Feb; 51(1):123-131. PubMed ID: 27103500
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.
Ziegler M; Landsburg D; Pegues D; Bilker W; Gilmar C; Kucharczuk C; Gorman T; Bink K; Moore A; Fitzpatrick R; Stadtmauer EA; Mangan P; Kraus K; Han JH
Biol Blood Marrow Transplant; 2019 May; 25(5):1004-1010. PubMed ID: 30481595
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the rates of Clostridium difficile and bacteremia after delaying fluoroquinolone prophylaxis from day 0 to day +3 post autologous stem cell transplantation.
Koseck K; Steinberg A; Caliendo G; Meyer J; Kim SS
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28456140
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Febrile Neutropenia in Autologous Hematopoietic Stem Cell Transplant (HSCT) Recipients on levofloxacin prophylaxis.
Signorelli J; Zimmer A; Liewer S; Shostrom VK; Freifeld A
Transpl Infect Dis; 2020 Apr; 22(2):e13225. PubMed ID: 31785022
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients.
Lutfi F; Skelton Iv WP; Wang Y; Rosenau E; Farhadfar N; Murthy H; Cogle CR; Brown R; Hiemenz J; Wingard JR; Norkin M
Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):23-31. PubMed ID: 31629722
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
16. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
Kaya AH; Tekgunduz E; Akpinar S; Batgi H; Bekdemir F; Kayikci O; Namdaroglu S; Ulu BU; Dal MS; Cakar MK; Korkmaz S; Altuntas F
Transplant Proc; 2017 Oct; 49(8):1911-1915. PubMed ID: 28923647
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
18. Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
Landau H; Wood K; Chung DJ; Koehne G; Lendvai N; Hassoun H; Lesokhin A; Hoover E; Zheng J; Devlin SM; Giralt S
Leuk Lymphoma; 2016 Aug; 57(8):1781-5. PubMed ID: 26758672
[TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin vs. levofloxacin for prophylaxis in recipients of hematopoietic stem cell transplantation.
Rambaran KA; Seifert CF
J Oncol Pharm Pract; 2019 Jun; 25(4):884-890. PubMed ID: 30041584
[TBL] [Abstract][Full Text] [Related]
20. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
